

[Back](#)

Investigating the Dual-Action Potential of (Z)-6-methoxy-2-(naphthalen-1-ylmethylene) Benzofuran-3(2H)-one (AU-23): A Novel Synthetic Aurone Derivative with Antibacterial and Anti-Inflammatory Activity

[Indian Journal of Pharmaceutical Education and Research](#) • Article • Open Access • 2025 • DOI: 10.5530/ijper.20255518

[Elsalami, Rabia Mrehil](#)^a; [Rullah, Kamal](#)^b; [Kassab, Yaman Walid](#)^{c,i}; [Qureshi, Mohammad Javed](#)^d; [Ahmad, Waqas](#)^e; [+6 authors](#)

^aDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, University of Cyberjaya, Cyberjaya, Malaysia

[Show all information](#)

0

Citations

[Full text](#) ▾ [Export](#) ▾ [Save to list](#)

Document	Impact	Cited by (0)	References (55)	Similar documents
----------	--------	--------------	-----------------	-------------------

Abstract

Aim/Background: Aurone is a well-known, naturally occurring, minor flavonoid with significant biological properties. However, their low abundance in nature limits their application in the medical field. In this study, we investigated the antimicrobial and anti-inflammatory properties of a novel synthetic aurone, (Z)-6-methoxy-2-(naphthalen-1-ylmethylene) benzofuran-3(2H)-one (AU-23). **Materials and Methods:** AU-23 was synthesized via multistep synthesis reactions involving the oxidative cyclization of 2'-hydroxychalcones. AU-23 was tested for antibacterial, minimum inhibitory concentration and antibiofilm activity against several ATCC strains using agar well diffusion, broth-micro dilution and XTT assay methods respectively. **Results:** At various concentrations, it selectively inhibited the growth of four strains (*P. aeruginosa* ATCC 9027, methicillin-resistant *S. aureus* (MRSA) ATCC 33591, methicillin-sensitive *Staphylococcus aureus* (MSSA) ATCC 25923 and methicillin-resistant *S. aureus* (MRSA) ATCC 43300). Moreover, it was observed that AU-23 had a bactericidal effect on sensitive strains of MSSA ATCC 25923 and *P. aeruginosa* ATCC 9027, as well as a bacteriostatic effect on MRSA ATCC 33591 and MRSA ATCC 43300. AU-23 also displayed effective antibiofilm activity against monomicrobial biofilms but not against polymicrobial biofilms. The findings of PCR study revealed that AU-23 downregulates the expression of pro-inflammatory cytokines and mediators (i.e., IL-6, IL-1 β , iNOS and TNF- α), as well as crucial pattern recognition receptors (TLR4 and CD14) in LPS-stimulated RAW 264.7 cells. Molecular docking studies demonstrated that the ability of AU-23 to bind to the mouse TLR4/MD-2 complex was comparable to that of dexamethasone. **Conclusion:** the results of several studies conducted, suggests that AU-23 has the potential to function as an effective dual-action agent with antimicrobial and anti-inflammatory properties. © Author (s) 2025.

Author keywords

Anti-inflammatory activity; Antibiofilm activity; Antimicrobial activity; Aurone; Docking study

Indexed keywords

EMTREE drug terms

1 (2 hydroxy 4 methoxyphenyl) 3 (naphthalen 1 yl) prop 2 en 1 one; 6 methoxy 2 (naphthalen 1 ylmethylene) benzofuran 3(2H) one; dexamethasone; flavanoid; gentamicin; interleukin 1beta; interleukin 6; lipopolysaccharide; nitric oxide; toll like receptor 4; tumor necrosis factor; unclassified drug; vancomycin

EMTREE medical terms


action potential; agar diffusion; antibacterial activity; antibiofilm activity; antiinflammatory activity; antimicrobial activity; apoptosis; Article; bacterial growth; bacterial strain; bactericidal activity; carbon nuclear magnetic resonance; cell culture; cell viability; chemical structure; chromatography; colony forming unit; cyclization; cytotoxicity; electrospray mass spectrometry; enzyme linked immunosorbent assay; *Escherichia coli*; field study; flow cytometry; hydrogen bond; IC50; MCF-7 cell line; methicillin resistant *Staphylococcus aureus*; minimum bactericidal concentration; minimum inhibitory concentration; molecular docking; nuclear magnetic resonance; proton nuclear magnetic resonance; *Pseudomonas aeruginosa*; RAW 264.7 cell line; real time polymerase chain reaction; reverse transcription polymerase chain reaction; RNA extraction; *Staphylococcus aureus*; XTT assay

Reaxys Chemistry database information


Reaxys is designed to support chemistry researchers at every stage with the ability to investigated chemistry related research topics in peer-reviewed literature, patents and substance databases. Reaxys retrieves substances, substance properties, reaction and synthesis data.

Substances


[View all substances \(10\)](#)




[View details](#)




[View details](#)



[View details](#)



[View details](#)



[View details](#)



Powered by **Reaxys**

Device trade names

Commercial names given to devices, used for branding and differentiation in the market, commonly referenced in scientific and clinical research.

Tradename	Country	Manufacturer
UCSF Chimera 1.14 package		
Discovery Studio DS 3.1	United States	Accelrys
HiScript III 1st Strand cDNA Synthesis Kit	China	Vazyme
Eppendorf realplex 4 qPCR Real-Time PCR Thermocycler machine		
Varioskan Flash		
LSR Fortessa CELL ANALYZER	United States	Becton Dickinson
ChemDraw Professional 15.0	United States	Perkin Elmer
GraphPad Prism version 9.0		

Chemicals and CAS Registry Numbers

Unique identifiers assigned by the Chemical Abstracts Service (CAS) to ensure accurate identification and tracking of chemicals across scientific literature.

dexamethasone	50-02-2
gentamicin	1392-48-9, 1403-66-3, 1405-41-0
nitric oxide	10102-43-9
toll like receptor 4	203811-83-0
vancomycin	1404-90-6, 1404-93-9

Funding details

Details about financial support for research, including funding sources and grant numbers as provided in academic publications.

Funding sponsor	Funding number	Acronym
Mohammed Al-Sayaghi		
Universiti Putra Malaysia See opportunities by UPM		UPM
Ms Asma Hamad		
University of Cyberjaya See opportunities by UoC	URGS/02/03/2022	UoC
University of Cyberjaya See opportunities by UoC		UoC

Funding text 1
The authors are thankful to the technicians at the University of Cyberjaya (UoC) and the immunology laboratory at the University of Putra Malaysia (UPM) and Ms Asma Hamad and Mohammed Al-Sayaghi, for their kind assistance during the research. We extend our thanks to Al-Bayan University, Iraq for their kind sponsoring and support to this study. The authors express appreciation to the University of Cyberjaya (UoC) for this research through project grant number URGS/02/03/2022.

Funding text 2
The authors express appreciation to the University of Cyberjaya (UoC) for this research through project grant number URGS/02/03/2022.

Corresponding authors

Corresponding author	N. Mohamad
Affiliation	Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Cyberjaya, Cyberjaya, 63000, Malaysia
Email address	najwa@cyberjaya.edu.my

© Copyright 2025 Elsevier B.V., All rights reserved.

- Abstract
- Author keywords
- Indexed keywords
- Reaxys Chemistry database information
- Device trade names
- Chemicals and CAS Registry Numbers
- Funding details
- Corresponding authors

About Scopus

- [What is Scopus](#)
- [Content coverage](#)
- [Scopus blog](#)

[Scopus API](#)
[Privacy matters](#)

Language

[日本語版を表示する](#)
[查看简体中文版本](#)
[查看繁體中文版本](#)
[Просмотр версии на русском языке](#)

Customer Service

[Help](#)
[Tutorials](#)
[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗ [Cookies settings](#)

All content on this site: Copyright © 2026 [Elsevier B.V.](#) ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

